Genzyme/Third Wave
This article was originally published in The Gray Sheet
Executive Summary
Firms form preferred marketing relationship for Third Wave's Invader UGT1A1 molecular assay, which assesses the potential of adverse reactions to the chemotherapy drug Camptosar (Pfizer) for colorectal cancer. The test was 510(k)-cleared in August (1"The Gray Sheet" Aug. 29, 2005, p. 26). Genzyme announced exclusive diagnostic rights to the UCLA Jonsson Cancer Center's discovery of gene mutations associated with drug resistance to Novartis' Gleevec, used to treat chronic myeloid leukemia, Oct. 6...
You may also be interested in...
FDA Clears Third Wave Invader Pharmacogenetic Test
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.